Shares of Viking Therapeutics plummeted more than 43% Tuesday after the company revealed poorer-than-expected mid-stage trial data for its experimental weight-loss pill, joining Eli Lilly with similar historic losses as pharmaceutical firms compete to develop an oral weight-loss drug.
Source: Original Article